LIXTE Biotechnology and Spanish Sarcoma Group Enroll First Patient in Phase 1b/2 Trial of LB-100 for Soft Tissue Sarcomas

Lixte Biotechnology has enrolled the first patient in a Phase 1b/2 trial of LB-100 and doxorubicin for advanced soft tissue sarcomas. The aim of the study is to find the appropriate dose of LB-100 with a standard dose of doxorubicin, followed by a randomized Phase 2 trial exploring synergy between the two drugs. Lixte hopes that this combination will improve efficacy exhibited by doxorubicin alo..